Hidradenitis suppurativa News and Research

RSS

Novel scoring system can distinguish between two serious skin diseases

Your skin becomes red and spots filled with pus appear, so you visit a dermatologist. When these symptoms spread to the skin throughout the body, it is difficult for the physician to distinguish whether it is generalized pustular psoriasis (GPP) or acute generalized exanthematous pustulosis (AGEP), as both have similar symptoms.

18 Mar 2024

Henry Ford Health and MSU continue groundbreaking medical research initiative

Michiganders will continue to have the opportunity to advance medical research aimed at advancing individualized health care through a renewed award to Henry Ford Health + Michigan State University Health Sciences from the National Institutes of Health's (NIH) All of Us Research Program.

29 Jan 2024

Study uncovers higher prevalence of hidradenitis suppurativa in young Finns

A new study from the University of Oulu, Finland, provides new insights into a skin condition called hidradenitis suppurativa (HS).

16 Jan 2024

Non-melanoma skin cancer causing greater number of global deaths than melanoma, study finds

Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, the more serious form of skin cancer, a new study presented today at the European Academy of Dermatology and Venerology (EADV) Congress 2023 has found.

10 Oct 2023

Vegan diets and skin inflammatory disorders: whats the link?

Are skin disorders and inflammatory conditions associated with nutritional deficiencies in vegan diets?

12 Sep 2023

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of third and fourth coronavirus disease 2019 (COVID-19) vaccination doses on immunity against COVID-19 among immunocompromised adult patients.

9 Mar 2023

Survey: 'Healthy tan' and other myths about sun safety are alive in Europe, other countries

8 in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented today at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

9 Sep 2022

Novel skin imaging technology improves the accuracy of basal cell carcinoma diagnosis

A novel imaging technique significantly improves the accuracy of the diagnosis of basal cell carcinoma (BCC) – the most frequent skin cancer – compared to clinical and dermoscopic examinations alone, according to new research being presented at the 31st European Academy of Dermatology and Venereology Congress.

7 Sep 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Hidradenitis suppurativa (Syn. Acneinversa) is one of the most troublesome and complicated skin diseases. The anti-inflammatory drug adalimumab can improve symptoms; however, patients also often have to undergo surgery.

19 Aug 2021

Imbalance in gut microbiota could play a key role in progression of inflammatory skin disorder

Findings presented at today’s EADV 2021 Spring Symposium suggest that an imbalance in gut microbiota (dysbiosis), could play a significant role in the progression of inflammatory skin disease, Hidradenitis Suppurativa (HS).

7 May 2021

Study shows effectiveness of UV-C light for killing COVID-19 on N95 respirators

Dermatology researchers at Henry Ford Health System, in collaboration with a team at the University of Michigan, have demonstrated that certain N95 respirators tainted with COVID-19 can be effectively and safely decontaminated for reuse using ultraviolet-C light (UV-C), a method commonly utilized for treating rare skin diseases.

22 Sep 2020

Prevalence of itch in dermatological patients linked to depression, suicidal ideation and stress

Itch is a very common symptom in patients suffering from skin diseases. In a new multicenter cross-sectional study on the psychological burden of itch in the Journal of Investigative Dermatology, published by Elsevier, investigators report that the presence of itch in dermatological patients was significantly associated with clinical depression, suicidal ideation and stress.

29 Oct 2019

Dermatology experts publish guidelines for diagnosing, managing hidradenitis suppurativa

An international team of dermatology experts including two from Henry Ford Hospital in Detroit have published – for the first time in North America - guidelines for diagnosing and managing hidradenitis suppurativa, a chronic and debilitating skin disease for which there is no cure.

6 Aug 2019

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Dermcidin, an anti-microbial peptide normally found in human sweat, may play a role in the pathogenesis of this chronic skin disease hidradenitis suppurativa, according to a research team from the George Washington University.

26 Apr 2019

Survey: More than 52% of people living with debilitating skin condition wait over four years for a diagnosis

To mark HS (hidradenitis suppurativa) Awareness Week from 5-11 June 2017, the Champions for Change campaign calls for people who suspect they may have HS to go and see their GP without delay.

6 Jun 2017

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012